Late Complications of Allogenic Stem Cells Transplantation in Leukaemia

Tissue Engineering and Regenerative Medicine
Sharmilla Kanagasundram, Farhanaz Amini

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure leukaemia. However, long term complications of post transplantation interfere with the patients' full recovery. The objective of this review was to identify the various long term complications and to assess their individual prevalences. Electronic databases including PubMed, Google Scholar and Cochrane were searched for years 2004-2017. The keywords used were leukaemia, allogenic stem cell transplantation, prevalence, side effects, long term, delayed, adverse effects, complications and outcome. A total of ten articles were included for analysis. There were 5 prospective studies, 3 retrospective studies and 2 cross sectional studies. A total of 40,069 patients, (20,189 males and 17,191 females) participated in these 10 studies. The gender of 2689 patients were not disclosed. Most common late complications and prevalence were chronic graft versus host disease (43% at 5 years post HSCT), secondary tumor (21% at 20 years post HSCT), hypothyroidism (11% at 15 years), bronchiolitis obliterans (9.7% at 122 days), cardiovascular disease (7.5% at 15 years) and avascular necrosis (5.4% at 10 years). The prevalence of azoospermia was 71.1% and depression, 18%. For the...Continue Reading

References

Jul 5, 2002·The New England Journal of Medicine·Joseph H Antin
May 15, 2004·British Journal of Haematology·Meghan A Higman, Georgia B Vogelsang
Jul 25, 2008·Blood·Joel S Bennett
Oct 31, 2008·Blood·J Douglas RizzoH Joachim Deeg
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ian Nivison-SmithKenneth F Bradstock
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jason W ChienSteven Z Pavletic
Jan 13, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul J MartinBarry E Storer
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boglarka GyurkoczaBrenda M Sandmaier
Dec 4, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brandon K C AuJason W Chien
Jan 18, 2011·Hematology·Mohamad Mohty, Jane F Apperley
Jun 9, 2015·The Journal of Clinical Investigation·Marie BleakleyWarren D Shlomchik
Feb 11, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Claire M VajdicUNKNOWN CAST study investigators
Mar 4, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Fotios V MichelisHans A Messner

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.